drugset / Trial / NCT06277492
A First-In-Human Study of Single and Multiple Ascending Doses of Oral SUL-238 in Healthy Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
The goal of this randomized, double-blind, placebo-controlled, single-center study is to evaluate the safety, tolerability, pharmacokinetics of single and multiple oral doses of SUL-238 in healthy subjects (aged ≥40 years).
Timeline
- Start
- 2024-02-19
- Primary completion
- 2025-07-11
- Completion
- 2025-11-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SUL-238 | Unknown | 50 mg | Oral |
| Comparator | SUL-238 | Unknown | 100 mg | Oral |
| Comparator | SUL-238 | Unknown | 250 mg | Oral |
| Comparator | SUL-238 | Unknown | 500 mg | Oral |
| Comparator | SUL-238 | Unknown | 1000 mg | Oral |
| Comparator | SUL-238 | Unknown | 2000 mg | Oral |
Indications
No indication recorded.